跳至主要内容
临床试验/CTRI/2017/03/008172
CTRI/2017/03/008172尚未招募1 期

A feasibility and safety study of single application multi-fractionated high dose rate (HDR) brachytherapy in locally advanced cervical cancer

Tata Memorial Hospital0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Histologically diagnosed invasive cervical cancer (squamous carcinoma, adenosquamous carcinoma, adenocarcinoma)
  • 2) FIGO stage II B - IV A after thorough clinical examination and work-up investigation.
  • 3) Suitable for radical radiation therapy with/without chemotherapy, and also for brachytherapy boost.
  • 4)Accepts the Informed consent process and signs the form on his/her will.

排除标准

  • 1)Patients with vesico-vaginal fistula or recto-vaginal fistula at diagnosis.
  • 2)Patients at high risk of anaesthesia and patients with phobia /contra-indications to undergo MRI.
  • 3)Patients not suitable for brachytherapy.
  • 4)Metastatic disease beyond iliac on standard imaging.
  • 5)Vault cancers/recurrence.
  • 6)Previous history of pelvic radiation.
  • 7)Non-compliance to treatment.
  • 8)Medical or psychological illness precluding treatment protocol

研究者

相似试验